The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
The findings suggest these new combinations may be more effective at clearing residual disease than rituximab-based therapy.
Lost amid the headlining news at the Association American Society of Hematology meeting last week were significant research findings from VA...
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.